{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:35:01Z","timestamp":1767141301689,"version":"build-2238731810"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11060-021-03815-6","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T06:02:31Z","timestamp":1627711351000},"page":"207-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Role of 23.4\u00a0Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy"],"prefix":"10.1007","volume":"154","author":[{"given":"Nalee","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5426-0604","authenticated-orcid":false,"given":"Do Hoon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,31]]},"reference":[{"key":"3815_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrneurol.2013.83","volume":"9","author":"A Korfel","year":"2013","unstructured":"Korfel A, Schlegel U (2013) Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 9:317\u2013327. https:\/\/doi.org\/10.1038\/nrneurol.2013.83","journal-title":"Nat Rev Neurol"},{"key":"3815_CR2","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/jco.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35:2410\u20132418. https:\/\/doi.org\/10.1200\/jco.2017.72.7602","journal-title":"J Clin Oncol"},{"key":"3815_CR3","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/s1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, R\u00f6th A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leith\u00e4user M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, N\u00e4gele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036\u20131047. https:\/\/doi.org\/10.1016\/s1470-2045(10)70229-1","journal-title":"Lancet Oncol"},{"key":"3815_CR4","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/s2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Ros\u00e9e P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, S\u00f8nderskov G\u00f8rl\u00f8v J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol 4:e510\u2013e523. https:\/\/doi.org\/10.1016\/s2352-3026(17)30174-6","journal-title":"Lancet Haematol"},{"key":"3815_CR5","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/jco.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Molu\u00e7on-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol 37:823\u2013833. https:\/\/doi.org\/10.1200\/jco.18.00306","journal-title":"J Clin Oncol"},{"key":"3815_CR6","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/jco.2007.12.5062","volume":"25","author":"GD Shah","year":"2007","unstructured":"Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730\u20134735. https:\/\/doi.org\/10.1200\/jco.2007.12.5062","journal-title":"J Clin Oncol"},{"key":"3815_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11060-018-2856-y","volume":"139","author":"N Adhikari","year":"2018","unstructured":"Adhikari N, Biswas A, Gogia A, Sahoo RK, Garg A, Nehra A, Sharma MC, Bhasker S, Singh M, Sreenivas V, Chawla R, Joshi G, Kumar L, Chander S (2018) A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome. J Neurooncol 139:153\u2013166. https:\/\/doi.org\/10.1007\/s11060-018-2856-y","journal-title":"J Neurooncol"},{"key":"3815_CR8","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/jco.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31:3971\u20133979. https:\/\/doi.org\/10.1200\/jco.2013.50.4910","journal-title":"J Clin Oncol"},{"key":"3815_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4143\/crt.2014.46.3.261","volume":"46","author":"BH Kim","year":"2014","unstructured":"Kim BH, Kim IH, Park SH, Park CK, Jung HW, Kim TM, Lee SH, Heo DS (2014) Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma. Cancer Res Treat 46:261\u2013269. https:\/\/doi.org\/10.4143\/crt.2014.46.3.261","journal-title":"Cancer Res Treat"},{"key":"3815_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3857\/roj.2020.00052","volume":"38","author":"TH Lee","year":"2020","unstructured":"Lee TH, Lee JH, Chang JH, Ye SJ, Kim TM, Park CK, Kim IH, Kim BH, Wee CW (2020) Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma. Radiat Oncol J 38:35\u201343. https:\/\/doi.org\/10.3857\/roj.2020.00052","journal-title":"Radiat Oncol J"},{"key":"3815_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.adro.2018.07.001","volume":"3","author":"T Sheu","year":"2018","unstructured":"Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC (2018) Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol 3:639\u2013646. https:\/\/doi.org\/10.1016\/j.adro.2018.07.001","journal-title":"Adv Radiat Oncol"},{"key":"3815_CR12","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/jjco\/hyx120","volume":"47","author":"JS Park","year":"2017","unstructured":"Park JS, Lim DH, Ahn YC, Park W, Kim SJ, Kim WS, Kim K (2017) Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy. Jpn J Clin Oncol 47:995\u20131001. https:\/\/doi.org\/10.1093\/jjco\/hyx120","journal-title":"Jpn J Clin Oncol"},{"key":"3815_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s11060-017-2616-4","volume":"135","author":"HK Koh","year":"2017","unstructured":"Koh HK, Kim IH, Kim TM, Lim DH, Oh D, Cho JH, Kim WC, Kim JH, Chung WK, Jeong BK, Kang KM, Hong S, Suh CO, Kim IA (2017) Role of radiation therapy in primary central nervous system lymphoma: KROG 14\u201320 Collaborative Study of Brain and Lymphoma Committee. J Neurooncol 135:629\u2013638. https:\/\/doi.org\/10.1007\/s11060-017-2616-4","journal-title":"J Neurooncol"},{"key":"3815_CR14","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/jco.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O\u2019Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034\u20135043. https:\/\/doi.org\/10.1200\/jco.2005.13.524","journal-title":"J Clin Oncol"},{"key":"3815_CR15","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1200\/JCO.2020.38.15_suppl.2501","volume":"38","author":"AMP Omuro","year":"2020","unstructured":"Omuro AMP, DeAngelis LM, Karrison T, Bovi JA, Rosenblum M, Corn BW, Correa D, Wefel JS, Aneja S, Grommes C, Schaff L, Waggoner SE, Lallana EC, Werner-Wasik M, Iwamoto F, Robinson TJ, Donnelly E, Struve T, Won M, Mehta MP (2020) Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). J Clin Oncol 38:2501\u20132501. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.2501","journal-title":"J Clin Oncol"},{"key":"3815_CR16","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1586\/14737140.2013.829634","volume":"13","author":"S Dahiya","year":"2013","unstructured":"Dahiya S, Murphy ES, Chao ST, Stevens GH, Peereboom DM, Ahluwalia MS (2013) Recurrent or refractory primary central nervous lymphoma: therapeutic considerations. Expert Rev Anticancer Ther 13:1109\u20131119. https:\/\/doi.org\/10.1586\/14737140.2013.829634","journal-title":"Expert Rev Anticancer Ther"},{"key":"3815_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1200\/jco.2005.01.161","volume":"23","author":"PL Nguyen","year":"2005","unstructured":"Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23:1507\u20131513. https:\/\/doi.org\/10.1200\/jco.2005.01.161","journal-title":"J Clin Oncol"},{"key":"3815_CR18","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1212\/01.wnl.0000276986.19602.c1","volume":"69","author":"AF Hottinger","year":"2007","unstructured":"Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE (2007) Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69:1178\u20131182. https:\/\/doi.org\/10.1212\/01.wnl.0000276986.19602.c1","journal-title":"Neurology"},{"key":"3815_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdq548","volume":"22","author":"NB Khimani","year":"2011","unstructured":"Khimani NB, Ng AK, Chen YH, Catalano P, Silver B, Mauch PM (2011) Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy. Ann Oncol 22:979\u2013984. https:\/\/doi.org\/10.1093\/annonc\/mdq548","journal-title":"Ann Oncol"},{"key":"3815_CR20","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/s0140-6736(09)61299-x","volume":"374","author":"C Soussain","year":"2009","unstructured":"Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY (2009) CNS complications of radiotherapy and chemotherapy. Lancet 374:1639\u20131651. https:\/\/doi.org\/10.1016\/s0140-6736(09)61299-x","journal-title":"Lancet"},{"key":"3815_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/nor186","volume":"14","author":"DD Correa","year":"2012","unstructured":"Correa DD, Shi W, Abrey LE, Deangelis LM, Omuro AM, Deutsch MB, Thaler HT (2012) Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro-oncology 14:101\u2013108. https:\/\/doi.org\/10.1093\/neuonc\/nor186","journal-title":"Neuro-oncology"},{"key":"3815_CR22","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1200\/jco.1998.16.3.859","volume":"16","author":"LE Abrey","year":"1998","unstructured":"Abrey LE, DeAngelis LM, Yahalom J (1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16:859\u2013863. https:\/\/doi.org\/10.1200\/jco.1998.16.3.859","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s11060-021-03824-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000}}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03815-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T03:09:36Z","timestamp":1631502576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03815-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,31]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3815"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03815-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,31]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11060-021-03824-5","URL":"https:\/\/doi.org\/10.1007\/s11060-021-03824-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest or financial ties to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Health Institutional Review Boards of Samsung Medical Center (No. 2021-02-001).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for informed consent was waived because of the retrospective nature of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}